Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update

Clicks: 276
ID: 272813
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Introduction: JAK, which constitutively binds to some cytokine receptors, plays an important role in cytokine signaling. While JAK is comprised of JAK1, JAK2, JAK3, and Tyk2, more than 40 types of cytokines transmit signals through JAK. Baricitinib is reported to be highly effective in the tr …
Reference Key
s2019expertbaricitinib Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kubo S;Nakayamada S;Tanaka Y;;
Journal expert review of clinical immunology
Year 2019
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/30987474
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't Lupus Erythematosus Systemic / immunology arthritis rheumatoid / drug therapy* signal transduction / drug effects* yoshiya tanaka rheumatoid / immunology clinical trials phase iii as topic cytokines / immunology azetidines / therapeutic use* sulfonamides / therapeutic use* systemic / drug therapy* pmid:30987474 doi:10.1080/1744666x.2019.1608821 satoshi kubo shingo nakayamada rheumatoid / pathology janus kinases / immunology systemic / pathology signal transduction / immunology tyk2 kinase / immunology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.